Pepromene Bio, Inc.
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
BAFFR-CAR T cells
Phase 1
This phase I trial evaluates the side effects and best dose of BAFFR-CAR T cells in treating patients with B-cell Non-Hodgkin's Lymphoma (B-NHL) that has come back (recurrent) or does not respond to treatment (refractory). T cells are infection fighting blood cells that can kill cancer cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize BAFFR, a protein on the surface of cancer cells. These BAFFR-specific T cells may help the body's immune system identify and kill BAFFR+ cancer cells.}}
Study Type : | Interventional |
Estimated Enrollment : | 36 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL) |
Actual Study Start Date : | June 13, 2022 |
Estimated Primary Completion Date : | July 13, 2027 |
Estimated Study Completion Date : | June 13, 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: B-cell activating factor receptor-Chimeric antigen receptor T cells [BAFFR-CAR T cells] BAFFR-CAR T cells in participants with r/r B-NHL |
Biological: BAFFR-CAR T cells |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
City of Hope Medical Center
Duarte, California, United States, 91010